Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Strontium-90 is a radioactive isotope of strontium produced as a fission byproduct in nuclear reactors and during nuclear weapons detonations. It is a soft, silvery metal that decays by emitting beta radiation, with a half-life of approximately 29 years. Medically, controlled amounts of strontium-90 are used for superficial radiotherapy to treat certain cancers (such as bone tumors and some eye or skin cancers) and in vascular brachytherapy to prevent coronary restenosis. Its mechanism involves the emission of beta particles that deliver localized cytotoxic radiation to targeted tissues. Strontium-90 acts chemically similar to calcium, leading it to accumulate in bones and teeth if ingested or inhaled, which can cause bone cancer, leukemia, or other malignancies due to its radioactivity[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on strontium-90.